Brian Jefferson, MD
Interventional Cardiology · Nashville, TNNPI 1508830407
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $338,435 of the $546,527 with a category attached, or 61.9%. 40 manufacturers reported payments, led by Shockwave Medical, Inc at 46.8% of the total. Among interventional cardiology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 678 payments — averaging $806.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$256K
- Boston Scientific$188K
- Medtronic$28K
- Cardiovascular Systems Inc.$27K
- Abbott$17K
- Abiomed$8K
- plus $23K from 34 others
Across 258 payments — averaging $5924.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$789K
- Boston Scientific$276K
- M.a. Med Alliance S.A.$238K
- Shockwave Medical, Inc$122K
- Cardiovascular Systems Inc.$69K
- Abbott$31K
- plus $3K from 1 others
What the payments were for
- Consulting fees$108,65120%
- Speaking & faculty fees$338,43562%
- Grants$2220%
- Travel & lodging$46,1978%
- Food & beverage$44,8238%
- Education$8,2002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$239,263
- GENERAL VASCULAR ACCESS$64,114
- Coronary Orbital Atherectomy System$23,165
- GENERAL - THERAPIES$15,490
- Vascular Lithotripsy$14,811
- Xience V coronary stent system$11,050
- Diamondback Coronary$7,731
- Impella$7,377
- ASAHI PTCA Guide Wire$5,439
- CROSSBOSS$5,373
- CATHETERS - ARROW$5,200
- GENERAL - STENTS$4,422
- Indigo System$3,312
- POLARIS$3,000
- AORTIX SYSTEM$2,925
- General - Balloon Catheters$2,344
- ACCOLADE SR$1,875
- GUIDELINER$1,400
- GENERAL BALLOONS$1,250
- ROTABLATOR$1,200
How this compares
$546,527 in reported general payments places this provider in the 95th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 126 | $114,338 |
| EntrestoSacubitril/Valsartan | 60 | $59,936 |
| XareltoRivaroxaban | 25 | $30,690 |
| FarxigaDapagliflozin Propanediol | 26 | $21,160 |
| BrilintaTicagrelor | 16 | $14,952 |
| WegovySemaglutide | 11 | $13,954 |
| Atorvastatin Calcium | 210 | $2,797 |
| Prasugrel Hcl | 20 | $2,463 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 106 | $1,921 |
| Ezetimibe | 35 | $1,791 |
| Rosuvastatin Calcium | 79 | $1,782 |
| ClopidogrelClopidogrel Bisulfate | 143 | $1,648 |
| Metoprolol Succinate | 73 | $1,378 |
| Ranolazine ErRanolazine | 12 | $1,235 |
| Potassium Chloride | 38 | $851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $34 | $114,338126 claims |
| NovartisEntresto | $151 | $59,93660 claims |
| AstraZenecaFarxiga, Brilinta | $40 | $36,11242 claims |
| Johnson & JohnsonXarelto | $38 | $30,69025 claims |
| Novo NordiskWegovy | $21 | $13,95411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Nashville
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
- Michael MorseNashville$353K
- Nadia SuttonNashville$344K
- Samuel HorrNashville$246K
- Colin BarkerNashville$217K
- Leah RajNashville$88K
- Andrew GoodmanNashville$57K
- Jay PatelNashville$48K
- John RiddickNashville$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.